Omar Awad, MD
Ophthalmology · Woodbury, MNNPI 1619942174
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,700 of the $6,112 with a category attached, or 76.9%. 10 manufacturers reported payments, led by Shire North American Group Inc at 59.1% of the total. Reporting peaked in 2019 at $4,085 and has fallen 93.1% since, to $282 in 2025. Among ophthalmology clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 30 payments — averaging $203.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shire North American Group Inc$4K
- Kala Pharmaceuticals, Inc.$1K
- Alcon$800
- Glaukos Corporation$160
- Ocular Therapeutix, Inc.$156
- Biotissue Holdings Inc.$111
- plus $72 from 4 others
What the payments were for
- Consulting fees$4,70077%
- Food & beverage$1,41223%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shire North American Group Inc | 4 | $3,614 |
| Kala Pharmaceuticals, Inc. | 1 | $1,200 |
| Alcon | 12 | $800 |
| Glaukos Corporation | 4 | $160 |
| Ocular Therapeutix, Inc. | 1 | $156 |
| Biotissue Holdings Inc. | 4 | $111 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Oyster Point Pharma, Inc. | 1 | $22 |
| The Cameron-ehlen Group, Inc. | 1 | $14 |
| Sun Pharmaceutical Industries Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYSUVIS$1,200
- DEXTENZA$468
- ReSure Sealant$156
- LenSx$137
- AcrySof IQ VIVITY$113
How this compares
$6,112 in reported general payments places this provider in the 90th percentile of 330 ophthalmology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 595 | $23,350 |
| Cyclosporine | 14 | $8,355 |
| MoxifloxacinMoxifloxacin Hcl | 394 | $7,394 |
| Diclofenac Sodium | 338 | $3,843 |
| ValacyclovirValacyclovir Hcl | 44 | $2,332 |
| Latanoprost | 126 | $1,796 |
| Ketorolac Tromethamine | 27 | $547 |
| ErythromycinErythromycin Base | 24 | $337 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 13 | $315 |
| Dorzolamide Hcl | 17 | $241 |
| Timolol Maleate | 18 | $232 |
| Brimonidine Tartrate | 26 | $225 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 11 | $137 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 18 | $58 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Woodbury
- Edwin RyanMinneapolis$9.6M
- Mark LobanoffSt Louis Park$6.3M
- Richard LindstromBloomington$5.6M
- Thomas SamuelsonMinnetonka$435K
- Deborah RistvedtAlexandria$392K
- Yun-Sen ChuBloomington$222K
- Sophie BakriRochester$183K
- David HardtenMinneapolis$119K
- John ChenRochester$82K
- Christine LarsenBloomington$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.